Raphael Aml003 Phase III Multicenter Open-Label Randomized Trial To Evaluate Efficacy And Safety Of Cpi-613 In Combination With High Dose Cytarabine And Mitoxantrone (Cham) Compared To High Dose Cytarabine And Mitoxantrone (Ham) In Older Patients (≥
Posted Date: Jun 10, 2019
- Investigator: Zartash Gul
- Specialties: Cancer, Leukemia, Oncology
- Type of Study: Drug
To determine efficacy of Cytarabine and Mitoxantrone versus Cytarabine and Mitoxantrone in combination with CPI-613 in terms of CR in older patients with acute myeloid leukemia.
Criteria:
Adults Over 60 Years Of Age, Expected Survival Of >3 Months, No Previous Cytotoxic Chemotherapy Treatment, No Active Uncontrolled Bleeding, No History Of Other Malignancy In The Past 5 Years
Keywords:
Leukemia
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com